Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Отделение новых средств и методов терапии ФГУ ГНЦССП им. В.П.Сербского, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С., Александровский Ю.А., Ильина Н.А. и др. Иксел (милнаципран): обобщенные результаты клинического изучения селективного ингибитора обратного захвата серотонина и норадреналина (СИОЗСН) в России. 2000; 2 (4). 2. Аведисова А.С., Чахава К.О., Ершова Е.М. Иксел при терапии больных с депрессивным расстройством и неврологически обусловленным хроническим болевым синдромом. Психиат. и психофармакотер. 2005; 7 (3). 3. Александровский Ю.А., Аведисова А.С., Ромасенко Л.В. и др. Психиат. и психофармакотер. 2004; 6 (1). 4. Левин О.С. Болевой синдром при полиневропатиях: подходы к лечению. Невропатол. и психиат. 2007; 5 (1). 5. Селицкий Г.В., Каприн А.Д., Извозчиков С.Б. и др. Милнаципран (иксел) в лечении тревожно-депрессивных и сексуальных расстройств у больных с невоспалительным синдромом хронической тазовой боли. Тер. арх. 2007; 5: 81–4. 6. Табеева Г.Р., Азимова Ю.Э. Опыт применения милнаципрана в лечении синдрома хронической ежедневной головной боли. Боль. 2006; 3: 30–6. 7. Amelin AV, Tarasova SV, Ignatov IuD et al. Antidepressants with different action mechanisms in the treatment of chronic daily headache. Zh Nevrol Psikhiatr Im S.S.Korsakova. 2007; 107 (9): 38–44. 8. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163 (20): 2433–45. 9. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003; 4 (1): 42–5. 10. Blumer D, Heibronn M. Chronic pain as a variant of depressive disease. The pain-prone disorder. J Nerv Mental Disorders 1982; 170: 381–406. 11. Cazzola M, Sarzi-Puttini P, Buskila D, Atzeni F. Pharmacological treatment of fibromyalgia. Reumatismo 2007; 59 (4): 280–91. 12. Clauw DJ, Mease P, Palmer RH et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008. 13. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008; 20 (3): 246–50. 14. Dempsey J. Milnacipran for fibromyalgia. Issues Emerg Health Technol 2008; 114: 1–4. 15. Dyck B, Tamiya J, Jovic F et al. Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem 2008; 51 (22): 7265–72. 16. Fordyce WE. Fibromyalgia and related matters. Clin J Pain 2000; 16 (2): 181–2. 17. Gordon DB. Nonopioid and adjuvant analgesics in chronic pain management: strategies for effective use. Nurs Clin North Am 2003; 38 (3): 447–64. 18. Gendreau RM, Thorn MD, Gendreau JF et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32 (10): 1975–85. 19. Harris RE, Williams DA, McLean SA et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthritis Rheum 2005; 52 (11): 3670–4. 20. Harten P. Fibromyalgia syndrome: new developments in pharmacotherapy. Z Rheumatol 2008; 67 (1): 75–82. Rev. 21. Holman AJ. Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia. Curr Pain Headache Rep 2008; 12 (6): 393–8. 22. Ito M, Yoshida K, Kimura H et al. Successful treatment of trigeminal neuralgia with milnacipran. Clin Neuropharmacol 2007; 30 (3): 183–5. 23. Ikeda T, Ishida Y, Naono R et al. Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. Neurosci Res 2009; 63 (1): 42–6. 24. Jaracz J, Rybakowski J. Depression and pain: novel clinical, neurobiological and psychopharmacological data. Psychiatr Pol 2005; 39 (5): 937–50. 25. Kasper S. The psychiatrist confronted with a fibromyalgia patient. Hum Psychopharmacol 2009; 24 (S1): S25–30. 26. Kito S, Nakajima T, Koga Y. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Eur Psychiat 2005; 20 (4): 355. 27. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiat 2009; 31 (3): 206–19. 28. Lawson K. Emerging pharmacological therapies for fibromyalgia. Curr Opin Investig Drugs 2006; 7 (7): 631–6. 29. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008; 4 (6): 1059–71. 30. Lindsay PG, Wycoff M. The depression-pain syndrome and the response to antidepressants. Psychosomatics 1981; 22: 571–7. 31. Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 2006; 7 (7): 637–42. 32. Lindsley CW. Molecule of the month. FDA approves new treatment for fibromyalgia. Curr Top Med Chem 2009; 9 (2): 225. 33. Matsuzawa-Yanagida K, Narita M, Nakajima M et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 2008; 33 (8): 1952–65. 34. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol 2009; 24 (S1): S19–23. 35. Mease PJ, Clauw DJ, Gendreau RM et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36 (2): 398–409. 36. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004; 19 (Suppl. 1): S15–9. 37. Moret C, Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat 2006; 2 (4): 537–48. 38. Obata H, Saito S, Koizuka S et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005; 100 (5): 1406–10. 39. Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain. Pharmacol Biochem Behav 2007; 88 (2): 171–8. 40. Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc) 2008; 44 (9): 653–60. 41. Perrot S. Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Curr Opin Support Palliat Care 2008; 2 (2): 122–7. Rev. 42. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008; 8 (3): 177–89. 43. Perrot S. Medication to treat fibromyalgia? Rev Med Suisse 2007; 3 (116): 1575–8. 44. Pilowsky I. Psychiatric approaches to non-cancer pain. Acta Anaesthesiol Scand 1999; 43 (9): 889–92. 45. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007; 19 (2): 111–7. 46. Spaeth M, Briley M. Fibromyalgia: a complex syndrome requiring amultidisciplinary approach. Hum Psychopharmacol 2009; 24 (S1): S3–10. 47. Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg 2008; 106 (4): 1309–15. 48. Takeda R, Watanabe Y, Ikeda T et al. Analgesic effect of milnacipran is associated with c-Fos expression in the anterior cingulate cortex in the rat neuropathic pain model. Neurosci Res 2009. 49. Tanikawa H. Efficacy of milnacipran in patients with chronic orthopaedic pain including degenerative spondylosis and osteoarthritis. Int J Psychiatry Clin Practice 2002; 6: 255. 50. Toyofuku A, Kikuta T. Treatment of phantom bite syndrome with milnacipran – a case series. Neuropsychiatr Dis Treat 2006; 2 (3): 387–90. 51. Uceyler N, HКuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008; 59 (9): 1279–98. 52. Yokogawa F, Kiuchi Y, Ishikawa Y et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 2002; 95 (1): 163–8. 53. Vitton O, Gendreau M, Gendreau J et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004; 19 (Suppl. 1): S27–35. 54. Von Knorring L. The Experience of Pain in Patients with Depressive Disorders. A clinical and Experimental Study. Umea University Medical Dissertation, New Series N2, Umea University, 1975. 55. Von Knorring L, Perris C, Eisemann M et al. Pain as a symptom in depressive disorder. I. Relationship to diagnostic subgroup and depressive symtomatology. Pain 1983; 15: 19–26.